IRIS
MARTINI, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.519
AS - Asia 1.846
NA - Nord America 1.616
SA - Sud America 274
AF - Africa 24
OC - Oceania 2
Totale 6.281
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.576
RU - Federazione Russa 1.129
SG - Singapore 697
IE - Irlanda 474
CN - Cina 370
HK - Hong Kong 362
IT - Italia 355
BR - Brasile 244
DE - Germania 178
KR - Corea 131
GB - Regno Unito 95
VN - Vietnam 88
IN - India 63
FR - Francia 62
UA - Ucraina 54
JP - Giappone 40
FI - Finlandia 35
SE - Svezia 29
AT - Austria 24
CA - Canada 24
GR - Grecia 24
PK - Pakistan 24
TR - Turchia 21
CZ - Repubblica Ceca 12
NL - Olanda 12
AR - Argentina 10
PL - Polonia 10
EC - Ecuador 9
ID - Indonesia 9
MX - Messico 9
ZA - Sudafrica 9
BE - Belgio 7
IQ - Iraq 7
BD - Bangladesh 6
AZ - Azerbaigian 5
CH - Svizzera 4
ES - Italia 4
KG - Kirghizistan 4
MA - Marocco 4
DO - Repubblica Dominicana 3
KE - Kenya 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
GI - Gibilterra 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
EG - Egitto 1
GA - Gabon 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
LB - Libano 1
MY - Malesia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 6.281
Salva come PNG Salva come JPEG
Città #
Dublin 464
Moscow 381
Hong Kong 361
Singapore 334
Santa Clara 301
Chandler 220
Seoul 131
Jacksonville 94
Naples 81
Hefei 73
New York 71
Beijing 69
Dallas 63
Munich 61
Ashburn 57
Bremen 55
Princeton 54
Roxbury 54
Bengaluru 41
The Dalles 40
Los Angeles 32
Ann Arbor 30
Cambridge 30
Ho Chi Minh City 28
Caserta 25
Medford 24
Hanoi 20
São Paulo 17
Vienna 14
Rome 12
Boardman 11
Brno 11
Des Moines 11
Elora 11
Turku 11
Wilmington 11
Aversa 10
Milan 10
Nuremberg 10
Brooklyn 9
Falkenstein 9
Napoli 9
San Francisco 9
Helsinki 8
Lappeenranta 8
Rawalpindi 8
Rio de Janeiro 8
Tianjin 8
Brussels 7
Frankfurt am Main 7
Tokyo 7
Warsaw 7
Bologna 6
Dong Ket 6
Ercolano 6
Jinan 6
San Mateo 6
Shanghai 6
Woodbridge 6
Amsterdam 5
Bahawalpur 5
Baku 5
Battipaglia 5
Belo Horizonte 5
Campinas 5
Chennai 5
Columbus 5
Denver 5
Guangzhou 5
Haiphong 5
Istanbul 5
Jakarta 5
Mountain View 5
Nanjing 5
Anantapur 4
Bari 4
Bishkek 4
Boston 4
Da Nang 4
Guarulhos 4
Guayaquil 4
Houston 4
Johannesburg 4
London 4
Piscataway 4
Pozzuoli 4
Secaucus 4
Atlanta 3
Baghdad 3
Cape Town 3
Changsha 3
City of London 3
Council Bluffs 3
Curitiba 3
Curvelo 3
Delhi 3
Dhaka 3
Florence 3
Giugliano in Campania 3
Hyderabad 3
Totale 3.645
Salva come PNG Salva come JPEG
Nome #
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 146
Beyond N staging in colorectal cancer: Current approaches and future perspectives 145
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 137
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 126
AXL is an oncotarget in human colorectal cancer 126
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 113
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 111
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 108
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 107
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 103
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 101
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 100
Immunotherapy for head and neck cancer: Present and future 100
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 96
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 96
Clinical management of metastatic colorectal cancer in the era of precision medicine 95
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 94
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 94
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 93
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 93
Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress 92
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 91
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 91
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 88
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 87
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 86
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 85
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 85
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 84
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 83
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 83
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 82
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 82
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 82
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 80
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 80
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer 80
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 79
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 79
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 79
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 77
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 77
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 76
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 76
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 76
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 76
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 76
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 74
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 73
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 73
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 73
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 72
How I treat anal squamous cell carcinoma 72
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 71
Pimasertib hydrochloride 71
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 68
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 68
Implication of the Hedgehog pathway in hepatocellular carcinoma. 67
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 67
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy 67
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy 66
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 66
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 66
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 63
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 63
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 62
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 60
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 60
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer 58
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 56
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer 56
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update 55
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 53
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 52
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer 52
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 52
Targeting the EGFR signalling pathway in metastatic colorectal cancer 49
RNF43- And NOTCH1-mutated chemotherapy and Anti-EGFR-refractory colorectal cancer: Should clonality guide target prioritization with investigational therapies? 49
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer 47
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments 46
“Aging and epigenetic implications in radiotherapy: The promise of BNCT” 41
Totale 6.484
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 0 0 1 21 21 12 22 28 11
2021/2022399 8 12 7 7 78 9 33 7 20 48 48 122
2022/2023939 99 17 25 71 125 78 4 41 426 8 26 19
2023/2024473 49 22 13 19 135 74 17 16 8 9 36 75
2024/20251.603 42 39 30 63 215 219 174 186 208 175 135 117
2025/20262.562 297 316 307 258 566 818 0 0 0 0 0 0
Totale 6.484